Analysts predict 10x Genomics will reach cashflow breakeven before depleting its cash reserves. The company appears well-positioned to fund its growth, with options to raise more capital through share issuance or debt.
James Wilbur's share sale prompts doubts about insiders’ view of stock's worth. No insider buying in past year may hint at uncertainty in company's future, despite high insider ownership suggesting management's awareness of shareholders' interests.
10x Genomics股票討論區
暫無評論